Aspira Women's Health Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Sandy Milligan

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	1.6yrs

Son yönetim güncellemeleri

Recent updates

Aspira Women’s Health slips 23% on common stock offering

Aug 22

Aspira Women’s Health GAAP EPS of -$0.07 in-line, revenue of $2.06M misses by $0.34M

Aug 10

Is Aspira Women's Health (NASDAQ:AWH) Using Too Much Debt?

Aug 02

CEO

Sandy Milligan (60 yo)

less than a year

Görev süresi

Dr. Sandra Milligan, also Known as Sandy, M.D. J.D. serves as President of Aspira Women's Health Inc. since April 01, 2024 and serves as its Interim CEO since December 16, 2024. She serves as an Independen...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sandra Milligan	Interim CEO & President	less than a year	Veri yok	Veri yok
John Kallassy	Chief Financial Officer	less than a year	Veri yok	Veri yok
Nicolette Possemato	Senior Vice President of Human Resources	2.8yrs	Veri yok	Veri yok
Michelle Snider	Senior Vice President of Commercial Strategy & Operations	1.3yrs	Veri yok	Veri yok

1.0yrs

Ortalama Görev Süresi

Deneyimli Yönetim: AWH 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ellen Vos	Independent Director	1.6yrs	US$115.58k	0.35% $ 44.7k
Daniel Chan	Member of Scientific Advisory Board	18.5yrs	Veri yok	Veri yok
Jannie Herchuk	Independent Chair of the Board	1.6yrs	US$118.83k	0.34% $ 44.0k
Stefanie Cavanaugh	Independent Director	1.6yrs	US$113.96k	0.37% $ 46.9k
Winfred Parnell	Independent Director	1.5yrs	US$100.84k	0.33% $ 42.9k
Donald Munroe	Member of Scientific Advisory Board	no data	US$484.75k	Veri yok
Judith Wolf	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Bristow	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Calaneet Balas	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Farr Nezhat	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Celeste Fralick	Independent Director	2.8yrs	US$178.00k	0.27% $ 35.2k
Leo Twiggs	Chairman of Clinical Advisory Board	1.2yrs	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AWH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.6 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 11:18
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Aspira Women's Health Inc. 12 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
Benjamin Haynor	Alliance Global Partners
Laura McGuigan	B. Riley Securities, Inc.

Aspira Women's Health Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aspira Women's Health Inc. Announces Departure of Nicole Sandford as Board Member

Aspira Women's Health Inc. Appoints John Kallassy as Interim Chief Financial Officer, Effective August 15, 2024

Aspira Women’s Health Inc Appoints John Ragard to Its Board of Directors

Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024

Aspira Women's Health Inc., Annual General Meeting, May 13, 2024

Aspira Women's Health Inc. Announces Executive Changes

Recent updates

Aspira Women's Health Inc. Announces Departure of Nicole Sandford as Board Member

Aspira Women's Health Inc. Successfully Reaches the First Milestone of the Advanced Research Projects Agency for Health $10 Million Award

Aspira Women's Health Inc. announced delayed 10-Q filing

Aspira Women's Health Inc. to Report Nine Months, 2024 Results on Nov 14, 2024

Aspira Women's Health Inc. Announces Its Selection Receive $10 Million Award from Advanced Research Projects Agency for Health’s Sprint for Women's Health

Aspira Women's Health Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. Appoints John Kallassy as Interim Chief Financial Officer, Effective August 15, 2024

New major risk - Shareholder dilution

Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $4.45 million.

Aspira Women's Health Inc. to Report Q2, 2024 Results on Aug 12, 2024

Aspira Women’s Health Inc Appoints John Ragard to Its Board of Directors

New major risk - Shareholder dilution

Aspira Women's Health Inc. announced that it has received $1.910249 million in funding

Aspira Women’s Health Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2)

Aspira Women's Health Inc. announced that it expects to receive $1.935051 million in funding

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Aspira Women's Health Inc. to Report Q1, 2024 Results on May 15, 2024

Aspira Women's Health Inc. Enhances Its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of Ovawatch

Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024

Consensus revenue estimates decrease by 23%, EPS upgraded

Consensus revenue estimates decrease by 23%, EPS upgraded

Aspira Women's Health Inc., Annual General Meeting, May 13, 2024

Price target decreased by 41% to US$3.30

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Inc. to Report Q4, 2023 Results on Mar 28, 2024

Price target increased by 24% to US$5.60

Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $5.50031 million.

Aspira Women's Health Inc. Announces Resignation of Veronica G.H. Jordan from the Board of Directors

Aspira Women's Health Provides Development Update on its Portfolio of Noninvasive Tests for Endometriosis

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Consensus revenue estimates decrease by 13%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. to Report Q3, 2023 Results on Nov 13, 2023

High number of new directors

Aspira Women's Health Sees Poster on its MiRNA-Based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

Aspira Women's Health Establishes A New Clinical Advisory Board

Aspira Women’s Health Regains Nasdaq Compliance

Aspira Women’s Health Announces Executive Changes

Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations

Consensus EPS estimates upgraded to US$2.13 loss, revenue downgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women’S Health Inc. Announces Resignation of Ryan Phan as Chief Scientific and Operating Officer, Effective September 15, 2023

Aspira Women's Health Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Share price stability

Aspira Women’s Health Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors, Member of Nominating and Corporate Governance Committee

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors

High number of new and inexperienced directors

Consensus revenue estimates decrease by 13%

Aspira Women's Health Inc. Announces Chief Financial Officer Changes, Effective June 15, 2023

First quarter 2023 earnings released: US$0.73 loss per share (vs US$1.24 loss in 1Q 2022)

Aspira Women's Health Inc. Appoints Three New Members to Its Board of Directors

Full year 2022 earnings: EPS exceeds analyst expectations

Aspira Women’s Health Inc. Announces Publication of Real-World Data Validating Use of OvaWatch for Management of Adnexal Masses

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Receives A Written Notice from Nasdaq

Aspira Women's Health Inc. Announces the Commercial Launch of OvaWatch

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. to Report Q3, 2022 Results on Nov 10, 2022

Aspira Women's Health Inc. Announces Publication of Its Second-Generation Multivariate Index Assay, Overa®, in the Detection of Cancer in Filipino Women

Aspira Women's Health Inc. has completed a Follow-on Equity Offering.

Aspira Women’s Health slips 23% on common stock offering

Consensus forecasts updated